Citadel Advisors
CLYM

Citadel Advisors’s Climb Bio CLYM Stock Holding History

Citadel Advisors’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9M Buy
1,297,972
+952,309
+276% +$9.84M ﹤0.01% 2803
2026
Q1 		$2.37M Buy
345,663
+106,620
+45% +$615K ﹤0.01% 5739
2025
Q4 		$956K Buy
+239,043
New +$574K ﹤0.01% 7495
2025
Q3 		– Sell
-138,392
Closed -$172K – 14448
2025
Q2 		$172K Buy
138,392
+55,638
+67% +$69.2K ﹤0.01% 10829
2025
Q1 		$101K Buy
82,754
+16,282
+24% +$26.4K ﹤0.01% 11448
2024
Q4 		$120K Buy
+66,472
New +$241K ﹤0.01% 11197
2022
Q4 		– Sell
-11,587
Closed -$37K – 15566
2022
Q3 		$37K Sell
11,587
-3,624
-24% -$11.6K ﹤0.01% 11800
2022
Q2 		$46K Buy
+15,211
New +$72K ﹤0.01% 11994

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's CLYM Position: Q2 2026 in Review

Citadel Advisors increased its Climb Bio (CLYM) stake by 276% in Q2 2026, buying an estimated $9.84M and bringing the position to 1,297,972 shares worth $16.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

Citadel Advisors first reported a position in CLYM in Q2 2022 and has held it in 8 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Citadel Advisors held 1,297,972 shares of Climb Bio worth $16.9M as of Q2 2026.
  • Citadel Advisors bought 952,309 Climb Bio shares in Q2 2026, an estimated $9.84M.
  • Climb Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2803 holding.
  • Citadel Advisors first reported a position in Climb Bio in Q2 2022 and has held it in 8 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.